Madrid December 17 (EUROPA PRESS). –
Researchers from Newcastle University, UK, showed that treatment with lenalidomide treatment for newly diagnosed patients improves survival in patients with bone marrow cancer.
The results are published in the journal «The Lancet Oncology, showing improvement for those who received continuous treatment with this drug compared with those who did not. The results of the study determined that long-term treatment with lenalidomide – known as «» Revlimid with Celgene- doubles the duration of remission and improve survival in young patients, nearly 8 percent.
This study, more style, hope to return in patients with multiple myeloma or bone marrow cancer, cancer treatment is difficult. Myeloma with 39 & # is a cancer of plasma cells, and can affect various areas of the body such as the spine, skull, pelvis, and ribs. Current treatment usually involves chemotherapy and stem cell transplantation.
Professor Graham Jackson, Northern Institute for Cancer Research at the University of Newcastle, and consultant hematologist Freeman Hospital in Newcastle, who led the study across the UK. "This is a breakthrough because it shows that prolonged use of lenalidomide significantly improves the time patients with myeloma remains in remission after initial therapy," he said.
"This is a big step and, more importantly, determines that for younger patients, lenalidomide improves the overall survival rate for this cancer is difficult to treat bone marrow. Our study emphasizes that lenalidomide should be considered for patients with newly diagnosed after stem cell transplantation, "he added.
The study, which lasted for seven years, was attended by more than 4,000 patients in 110 hospitals in the UK and is mainly funded by Cancer Research UK, with the support of Myeloma UK and a variety of educational grants. In the study, a total of 1137 patients were first diagnosed, randomized, maintenance therapy with lenalidomide and 834 patients, according to the observations, it was concluded after their initial treatment.
The results show that lenalidomide may extend the average time of remission for more than two years in younger patients and in more than one year in patients older and less fit. Reducing the risk of progression or death by more than 50% in both groups.
The study was conducted by the Division of research for clinical trials at the University of Leeds and research experts from hospitals across the UK.
Professor Gordon Cook, clinical director of the Research Institute of Clinical Research at the University of Leeds, co-wrote and believes that lenalidomide should be available on the NHS. "Our findings suggest that lenalidomide can significantly extend the life of people living with myeloma, in the largest trial to date. This treatment is not available on the NHS for this group of patients, and it is an unmet need, "he added.
In addition, the results confirm the findings of three much smaller studies have shown that after transplantation of stem cells, lenalidomide reduces the risk of disease progression or death by 50% compared with placebo or no treatment,